9 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 8 |
| Massachusetts Institute Of Technology | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18734176 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DAVIS, BRIAN J | 1614 | Non-Final OA | Jun 05, 2024 |
| 18481451 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | Massachusetts Institute Of Technology | BRAUN, MADELINE E | 1624 | Non-Final OA | Oct 05, 2023 |
| 18469467 | COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN AND BREAST CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SAMSELL, RILLA MARIE | 1624 | Non-Final OA | Sep 18, 2023 |
| 18297979 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | AEDER, SEAN E | 1642 | Non-Final OA | Apr 10, 2023 |
| 18193917 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | AEDER, SEAN E | 1642 | Final Rejection | Mar 31, 2023 |
| 18145595 | UREA INHIBITORS OF MICRO-RNA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JOHNSON, CHRISTOPHER LINDSAY | 1691 | Final Rejection | Dec 22, 2022 |
| 17663133 | LUNG TARGETED ANTICANCER THERAPIES WITH LIPOSOMAL ANNAMYCIN | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JONES, DAMERON LEVEST | 1618 | Final Rejection | May 12, 2022 |
| 17584116 | COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN AND BREAST CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | HUTTER, GILLIAN A | 1625 | Non-Final OA | Jan 25, 2022 |
| 17310262 | METAL CHELATOR COMBINATION THERAPY FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JOHANSEN, PETER N. | 1644 | Final Rejection | Jul 27, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial